#ESMO25: Enhertu could move into 'curative' breast cancer setting on the strength of Phase 3 data

BERLIN – AstraZeneca and Daiichi Sankyo unveiled details of a late-stage success for their blockbuster drug Enhertu in an early form of breast cancer ahead of surgery where the companies believe it could help cure ...